Malignant Male Reproductive System Neoplasm

Malignant Male Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

6,225 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,451
Recruiting: 784
Ph III recruiting: 82
Growth YoY: +24.4%
Industry share: 18%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 27.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (762)

clinicaltrialsPublishedShowing 601–602 of 602 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00103428	Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer	terminated	Phase 1 / Phase 2	69	Cell GenesysINDUSTRY	1	Feb 2, 2006	clinicaltrials
NCT00179738	A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.	terminated	Phase 2	40	Celgene CorporationINDUSTRY	1	Nov 23, 2005